Scam, kidnap by South African police

Scam, kidnap by South African police

Medical Writing Institute click here

MJoTAtalks click here

Emerald Pademelon Press LLC click here


Peace Scientists click here

Dr Susanna loves the countries and the peoples of Africa

Scam, kidnap by South African police

Scam, kidnap by South African police

 
Bookmark and Share
Don't get diabetes! Take care of yourself if you have it! Diabetes resources, click here.
Diabetes News
Clinical trials testing therapies for diabetes

Latest Top (15) News


AT247, NovoRapid® and Fiasp® in Glucose Clamp Study
Condition:   Diabetes Mellitus, Type 1
Interventions:   Biological: NovoRapid;   Biological: Fiasp;   Biological: AT247
Sponsor:   Arecor Limited
Recruiting

Wed, 22 May 2019 12:00:00 EDT


Characteristics, Treatment, and Economic Burden of Patients With CVD,CKD or at High Cardiovascular Risk
Conditions:   Cardiovascular Abnormalities;   Chronic Kidney Diseases;   Diabetes
Intervention:  
Sponsor:   West China Hospital
Not yet recruiting

Wed, 22 May 2019 12:00:00 EDT


Effects of Short-term Intensive De-escalation Therapy on Long-term Regimen Simplification in Patients With Poorly Controlled Type 2 Diabetes
Conditions:   Poorly Controlled Diabetes Mellitus;   Intensive-de-escalation Therapy;   Long-term Regimen Simplification
Interventions:   Drug: CSII and thereafter combination therapy with wearable devices;   Drug: CSII and thereafter combination therapy;   Drug: Traditionally upgrading therapy
Sponsor:   Yanbing Li
Not yet recruiting

Wed, 22 May 2019 12:00:00 EDT


Effects of an Optimized 18-month Physical Exercise on (Early)-Postmenopausal Risk Factors in Women With Osteopenia and Osteoporosis
Condition:   Osteopenia, Osteoporosis
Interventions:   Other: High Intensity Resistance (HIT-RT) and Endurance exercise (HIIT);   Other: Wellness
Sponsor:   University of Erlangen-Nürnberg Medical School
Active, not recruiting

Wed, 22 May 2019 12:00:00 EDT


Efficacy of Black Seed Oil in Patients With Type 2 Diabetes Mellitus
Condition:   Diabetes Mellitus, Type 2
Interventions:   Dietary Supplement: Black Seed Oil;   Drug: Anti-Diabetics
Sponsor:   Ain Shams University
Active, not recruiting

Wed, 22 May 2019 12:00:00 EDT


GLP-1 REceptor Agonists and Real World EvIdeNce
Condition:   Type 2 Diabetes
Interventions:   Drug: Long-acting GLP-1RA;   Drug: Short-acting GLP-1RA;   Drug: Human-based GLP-1RA;   Drug: Exendin-based GLP-1RA;   Drug: Fixed ratio BI/GLP-1RA combination;   Drug: Flexible BI/GLP-1RA combination
Sponsors:   University of Padova;   Azienda Ospedaliera di Padova
Active, not recruiting

Wed, 22 May 2019 12:00:00 EDT


High Intensity Interval Training in Severe Mental Illness
Conditions:   Major Depressive Disorder;   Bipolar Disorder;   Schizophrenia
Intervention:   Other: High Intensity Interval Training (HIIT)
Sponsors:   King's College London;   National Institute for Health Research, United Kingdom;   South London and Maudsley NHS Foundation Trust
Not yet recruiting

Wed, 22 May 2019 12:00:00 EDT


Metabolic Responses of Dapagliflozin vs Sitagliptin in T2DM Patients Inadequately Controlled With Insulin Therapy
Conditions:   Type 2 Diabetes;   Ketonemia
Interventions:   Drug: Dapagliflozin 10 mg;   Drug: Sitagliptin 100mg
Sponsor:   The University of Hong Kong
Recruiting

Wed, 22 May 2019 12:00:00 EDT


Peer Support To Enhance The Shanghai Integration Model Of Diabetes Care: Dissemination To 12 Communities
Conditions:   Type2 Diabetes;   PreDiabetes
Intervention:   Behavioral: Peer Support Integrated with Primary Care
Sponsors:   Shanghai 6th People's Hospital;   University of North Carolina, Chapel Hill;   Merck Foundation
Not yet recruiting

Wed, 22 May 2019 12:00:00 EDT


Prevention Of Primary Foot Ulcers in High-risk Diabetes Patients
Conditions:   Diabetes Mellitus;   Foot Ulcer, Diabetic;   Primary Prevention
Intervention:   Device: 3D printed insoles for normal footware
Sponsors:   Countess of Chester NHS Foundation Trust;   University of Liverpool;   Staffordshire University
Not yet recruiting

Wed, 22 May 2019 12:00:00 EDT


Safety Evaluation of the Advanced Hybrid Closed Loop (AHCL) System
Condition:   Type 1 Diabetes Mellitus
Intervention:   Device: AHCL insulin pump system
Sponsor:   Medtronic Diabetes
Not yet recruiting

Wed, 22 May 2019 12:00:00 EDT


Clinical Efficacy of Telmisartan in Reducing Cardiac Remodeling Among Obese Patients With Hypertension
Condition:   Hypertension
Interventions:   Drug: telmisartan;   Drug: amlodipine
Sponsor:   First Affiliated Hospital Xi'an Jiaotong University
Not yet recruiting

Tue, 21 May 2019 12:00:00 EDT


Effect of Whole-body Vibration on TcPO2
Condition:   Diabetes Mellitus, Type 2
Intervention:   Other: Whole body Vibration exercise
Sponsors:   Instituto Nacional de Rehabilitacion;   Instituto Nacional de Ciencias Medicas y Nutricion Salvador Zubiran
Recruiting

Tue, 21 May 2019 12:00:00 EDT


Efficacy and Safety of Deep Sea Water on the Blood Glucose Level
Condition:   PreDiabetes
Intervention:   Dietary Supplement: Deep sea water
Sponsor:   Chonbuk National University Hospital
Completed

Tue, 21 May 2019 12:00:00 EDT


Feasibility of Simulation in Therapeutic Patient Education for Adult Diabetic Patients Using the Freestyle Libre® Device
Condition:   Insulin-Dependent Diabetes
Interventions:   Other: S-TPE;   Other: Questionnaires
Sponsor:   Centre Hospitalier Universitaire Dijon
Not yet recruiting

Tue, 21 May 2019 12:00:00 EDT
FDA (Food and Drug Administration) press releases. FDA makes sure of the safety of all medicines which can be injected, breathed in, rubbed in and swallowed, in the United States of America.

Latest Top (10) News


FDA Statement on the agency’s list of known nitrosamine-free valsartan and ARB class medicines, as part of agency’s ongoing efforts to resolve ongoing safety issue
FDA announces list of nitrosamine-free ARB medications confirmed by the agency to help patients and healthcare providers




FDA Warns Against the Use of Unauthorized Devices for Diabetes Management
FDA Warns Against the Use of Unauthorized Devices for Diabetes Management




FDA approves first anticoagulant (blood thinner) for pediatric patients to treat potentially life-threatening blood clots
The FDA approved Fragmin (dalteparin sodium) injection, for subcutaneous use, to reduce the recurrence of symptomatic venous thromboembolism (VTE) in pediatric patients one month of age and older.




FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder
FDA approves first treatment for children with Lambert-Eaton myasthenic syndrome, a rare autoimmune disorder




FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis
FDA approves new treatments for heart disease caused by a serious rare disease, transthyretin mediated amyloidosis




FDA issues warning letter to genomics lab for illegally marketing genetic test that claims to predict patients’ responses to specific medications
FDA issues warning letter to genomics lab for illegally marketing genetic test that claims to predict patients’ responses to specific medications




FDA takes action to protect women’s health, orders manufacturers of surgical mesh intended for transvaginal repair of pelvic organ prolapse to stop selling all devices
FDA informs companies that the agency is not approving their PMA applications and that they will have to remove their products from the market




FDA takes new enforcement actions as part of the agency’s ongoing effort to combat the illegal online sales of opioids
Agency issued two warning letters to operators of websites that illegally market potentially dangerous, unapproved and misbranded opioid medications.




FDA warns company for selling e-liquids that resemble kid-friendly foods as part of the agency’s ongoing Youth Tobacco Prevention Plan
FDA issued a warning letter to Electric Lotus LLC for selling nicotine-containing e-liquids used in e-cigarettes with labeling and/or advertising that cause them to resemble kid-friendly food products.




FDA warns manufacturers of products labeled as homeopathic for putting consumers at risk with significant violations of manufacturing quality standards
The U.S. Food and Drug Administration has posted warning letters to five companies who produce products labeled as homeopathic for significant violations of current good manufacturing practice (CGMP) regulations.


Diabetes news from the American Diabetes Association

Latest Top (5) News